

Financial Tearsheet

Company Overview

Kannalife, Inc. is a biopharmaceutical company focused on the development of proprietary and patented cannabidiol (CBD) and CBD-like molecules for patients suffering from unmet medical needs of neurodegenerative disorders - including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE) a disease associated with highly repetitive impact injuries in professional and amateur sports. The Company's family of proprietary molecules focuses on treating oxidative stress-related diseases such as HE, chronic pain from neuropathies like CIPN, and neurodegenerative diseases like CTE. Kannalife conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.

Recent Financial News

Date	Headline
Oct 06, 2020	Kannalife, Inc. Adds to Its Global IP Estate Receiving Patent Grant from Canada for Its Novel Anti-Inflammatory Compounds
Sep 17, 2020	Kannalife, Inc. Appoints Dr. Tague Honoré as Chairman of the Company's Board of Advisors
Aug 25, 2020	Kannalife, Inc. Receives Patent Grants in Additional European Territories
Jun 30, 2020	Kannalife, Inc. Bolsters IP Portfolio with Multiple Patents Issued in 12 Key European Territories
Jun 02, 2020	Kannalife, Inc. Appoints Terrence O. Tormey to the Company's Board of Advisors
















IR Contacts

Investor Relations	Transfer Agent
Investor Relations Firm CORE IR 377 Oak Street Garden City, NY 11530 (516) 222-2285 www.coreir.com Contact: John Marco Johnm@coreir.com	Securities Transfer Corp. 2901 Dallas Parkway, Suite 380, Plano, TX 75093 (469) 633-0101 www.stctransfer.com
Auditors	Corporate Counsel
DBB McKennon 12790 El Camino Real #130 San Diego, CA 92130 (858) 217-4035 www.dbbmckennon.com	Procopio, Cory, Hargreaves & Savitch LLP. 525 B Street, Suite 2200 San Diego, CA 92101 (619) 238-1900 www.procopio.com

Stock Performance

Today's Open	0.4500
Volume	39,140
Day Range	0.3625 - 0.4500
52 Week Range	0.3420 - 6.9000
Bid/Ask	0.3900 / 0.4850
Bid/Ask Size	2,500 X 6,800
Previous Close	0.3812
Market Cap	28.96 million
Shares Outstanding	74.25 million
Dividend/Yield	0.0000 / 0.0000%
EPS (TTM)	-0.057000
P/E Ratio (TTM)	N/A

Recent XBRL Filings

Filing Date ▼	Form Type	Description	View
Aug 12, 2020	10-Q	Quarterly report	  
May 14, 2020	10-Q	Quarterly report	  
Mar 30, 2020	10-K	Annual report	  
Nov 13, 2019	10-Q	Quarterly report	  
Aug 13, 2019	10-Q	Quarterly report	  

Management Team

Dean Petkanas, Chairman & CEO

William A. Kinney, PHD, Chief Scientific Officer

Thoma Kikis, Chief Communications Officer, Board Director

Mark Corrao, Chief Financial Officer

Board of Directors

Dean Petkanas, Chairman & CEO

Thoma Kikis, Founder / Chief Communications Officer, Board Director

Robert Malasek, Director

Blake Schroeder, Director

Timothy Scott, PhD, Director